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Abstract 1 
The schistosome blood flukes are one of the largest global causes of parasitic morbidity. Further 2 
study of the specific antibody response during schistosomiasis may yield the vaccines and 3 
diagnostics needed to combat this disease. Therefore, for the purposes of antigen discovery, sera and 4 
antibody secreting cell (ASC) probes from semi-permissive rats and sera from susceptible mice 5 
were used to screen a schistosome protein microarray. Following Schistosoma japonicum infection, 6 
rats had reduced pathology, increased antibody responses and broader antigen recognition profiles 7 
compared with mice. With successive infections, rat global serological reactivity and the number of 8 
recognized antigens increased. The local antibody response in rat skin and lung, measured with 9 
ASC probes, increased after parasite migration and contributed antigen-specific antibodies to the 10 
multivalent serological response. In addition, the temporal variation of anti-parasite serum 11 
antibodies after infection and reinfection followed patterns that appear related to the antigen driving 12 
the response. Among the 29 antigens differentially recognized by the infected hosts, were numerous 13 
known vaccine candidates, drug targets, and several S. japonicum homologues of human 14 
schistosomiasis resistance markers - the tegument allergen-like (TAL) proteins. From this set we 15 
prioritized eight proteins that may prove to be novel schistosome vaccine and diagnostic antigens. 16 
 17 
Introduction 18 
Schistosomiasis, a neglected tropical parasitic disease, affects over 250 million people globally.
1
 19 
Despite extensive chemotherapy programs, endemic populations remain at high risk of reinfection 20 
and eradication of the trematode worms require a combined approach incorporating public health 21 
measures, continued drug treatment and an effective vaccine.
2-4
 In addition, current serological and 22 
parasitological methods of diagnosis are insensitive and/or labor intensive and new diagnostic 23 
antibody tests are required.
4-6
 In contrast to the African forms, schistosomiasis japonica, caused by 24 
Schistosoma japonicum, is a true zoonosis, infecting a broad range of mammalian hosts; 46 species 25 
in total.
7
 Notably, immunity and infection severity varies considerably among these hosts allowing 26 
for comparison between susceptible and resistance traits. Of the laboratory animals, the mouse is 27 
fully permissive, passing viable schistosome eggs, whereas the rat (Rattus norvegicus) is semi-28 
permissive to both S. japonicum
7,8
 and S. mansoni
9-11
 infections. The resistant characteristics of the 29 
laboratory rat have been used for several decades in vaccine research
2,10
 and resulted in the 30 
identification of the only schistosome vaccine antigen, Sh28GST, currently in phase III trials.
4,12,13
 31 
Schistosomiasis-resistance increases with subsequent infections and is immunological in nature, 32 
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primarily due to antibody-dependent cell-mediated cytotoxicity (ADCC).
8,9,11,14
 The migration path 33 
of the schistosome parasite from skin to lung is critical for both immune priming and parasite 34 
elimination.
9,15,16
 Following infection with S. japonicum or S. mansoni cercariae the rat eliminates 35 
the parasites over the course of a few weeks, in the lungs and the liver; with the majority of the 36 
schistosomules never progressing past the lung.
16-18
 The few worms found in the liver are stunted, 37 
produce few fertile eggs and these worms are eventually eliminated by a self-cure 38 
phenomenon.
7,9,14,18
 Upon reinfection the challenge parasites are rapidly eliminated at or prior to the 39 
lung stage.
9,14,19,20
 Four to six weeks after a primary infection schistosome-specific immunoglobulin 40 
is produced that, together with complement, eosinophils, macrophages, platelets and mast cells, are 41 
able to form complexes and attack schistosomules;
9,21
 blocking of this antibody response reduces 42 
the resistance to reinfection.
11,15,21
 The predominantly humoral immunity of schistosomiasis 43 
resistance in the rat, compared to the susceptible mouse, makes this animal model ideal for antigen 44 
discovery. The specificity of the protective antibodies used by the rat are, however, largely 45 
unknown. 46 
 47 
As opposed to conventional serological screening approaches - such as probing of display libraries 48 
or parasite extracts - parallel screening with protein microarray technology,
22,23
 particularly when 49 
combined with resistance models in experimental animal hosts, may result in the discovery of more 50 
parasite-specific antigens. Ultimately these novel antigens may prove to include new and effective 51 
vaccine and diagnostic candidates. An additional consideration is that experimental infections have 52 
controlled infection parameters and thus avoid confounding variables found in endemic human field 53 
studies, such as incomplete clinical and drug treatment histories.
24
  54 
 55 
In this study we describe the use of a schistosome-specific protein microarray we have 56 
developed
23,25
 to: 1) compare the specific antibody response between resistant and susceptible 57 
animal hosts; 2) examine the longitudinal serum antibody response in the resistant rat host during 58 
successive infections; 3) define the tissue-specific local antibody response using antibody secreting 59 
cell (ASC) probes;
26,27
 and 4) discover new potential vaccine and diagnostic antigens. To achieve 60 
these objectives time courses of rats and mice experimentally infected with S. japonicum were 61 
completed to collect antibody samples for microarray probing and to characterize the parasitological 62 
resistance of these two animal models, particularly the striking resistance to reinfection intrinsic to 63 
the rat. In addition, antibodies generated from rat skin- and lung-draining lymph nodes were used to 64 
identify antigens specifically recognized at these important immunological sites of infection and 65 
parasite elimination.  66 
©    2015 Macmillan Publishers Limited. All rights reserved.
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Results 67 
Rats have reduced pathology and less viable parasites compared to mice 68 
Two separate time courses with rats and experimental infections with mice were completed. The 69 
first rat time course (TC1) measured serum responses after two successive infections with treatment 70 
groups having intervals of four (T4), six (T6) and eight (T8) weeks between infections. The second 71 
rat time course (TC2) measured the serum and local tissue responses following a primary infection 72 
(Group I), and five (Group I5) and nine days (Group I9) after a secondary challenge infection. 73 
Amongst the groups within TC1 and TC2 there was high variability for liver egg burdens 74 
(Supplementary Table 1) but worm numbers and worm lengths were similar. As expected the semi-75 
permissive rat host had few adult worms, the length of the perfused worms was reduced and few 76 
eggs were present in the liver (Supplementary Table 1). Indeed, less than 1% of the total cercarial 77 
challenge load was perfused as adult worms from the rat. Liver histology further highlighted the 78 
reduced pathology in the rat (Supplementary Figure 1A). Infected livers had low pathology and this 79 
was reflected in a low granuloma density (3% ± 0.6%; average ± SEM for all rat groups) despite the 80 
high cercarial challenge and the long duration of the infection. In addition, few of the eggs were 81 
viable; miracidial hatch testing resulted in very few hatched miracidia (1.5 miracidia hatched per 82 
1000 liver eggs for Group T4; data not shown). Notably, sections of rat lung contained schistosome 83 
larval stages nine days after a secondary cercarial challenge (Supplementary Figure 1C). It could not 84 
be determined if these parasites were under immune attack but the lung is recognized as an 85 
important site for the elimination of schistosomes.
9,17,19,28
 86 
 87 
To provide a standardized model to compare infection in the rat a CBA mouse infection, commonly 88 
used in schistosomiasis pathology studies,
29-31
 was also completed alongside the Swiss mouse strain 89 
used for serological analysis. Both mouse strains had similar burdens of infection (data not shown) 90 
but the CBA infection was used for detailed parasitological and histological comparisons. The 91 
permissive mouse had a higher parasite burden and pathology than the rat. Six weeks post-infection, 92 
47% of cercariae were perfused as adults and the male and female worms were approximately two- 93 
and three-fold longer, respectively, than those from the rat (Supplementary Table 1). Liver 94 
pathology was also higher in the mouse infection (Supplementary Figure 1B). Granuloma density 95 
was four times higher in infected mouse livers (14.7% ± 2.1%) compared with infected rat liver. 96 
Additionally, egg viability was much higher (43.7 miracidia hatched per 1000 liver eggs). Despite 97 
some differences in the experimental infections used for the rat and mouse models (e.g. number of 98 
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infections and cercariae per infection) these data clearly highlight the variation of susceptibility of 99 
the two rodent hosts to schistosome infection. 100 
 101 
Protein microarray reactivity varied between hosts and antibody source 102 
Protein microarray production was characterized by high cloning and protein expression efficiencies 103 
and quality control (QC) measures.
25,32
 For the primary purpose of vaccine and diagnostic antigen 104 
discovery, the 289 feature schistosome protein microarray (Supplementary Table 2) was probed 105 
with 72 sera, ASC probes and bronchoalveolar lavage (BAL) fluid samples from the rat 106 
experimental infections. The pre-infection time point samples were compared with primary and 107 
secondary infection time points to identify differentially reactive proteins. In the case of the ASC 108 
probes, the skin and lung samples were compared with pooled BAL fluid and liver and spleen and 109 
uninfected ASC probes to identify antigens recognized in the skin- and lung-draining lymph nodes. 110 
A time course was completed for nine individual Swiss mice (MTC). Pre-infection and post-111 
infection mouse serum samples (18 in total) were collected as a susceptible host comparison for the 112 
semi-permissive rat samples. The raw protein microarray signal intensity (SI) (Supplementary Table 113 
3) for all 90 biological samples was normalized (Supplementary Table 4) and heatmaps created for: 114 
(1) the individual samples for all the protein microarray features (Figure 1); (2) group averaged SI 115 
for the most reactive antigens in TC1 and TC2 samples (Figure 2); and (3) individual SI for the 116 
most reactive antigens in the MTC and ASC probe samples (Figure 3).  117 
Within all the probed and normalization microarrays, the “No DNA” negative controls had low 118 
overall reactivity and were, on average, 2-3 times lower than the remaining protein microarray 119 
features, and at least 10-fold less than the IgG positive control (Figures 1-3). Uninfected serum 120 
reactive against the schistosome protein microarray was weak; however, reactivity increased with 121 
parasite challenge (Figures 1A-C and Supplementary Figure 2), and this was also confirmed by anti-122 
adult parasite extract (SWAP) antibodies measured by ELISA (data not shown). In both rat time 123 
courses there was no significant difference (ANOVA, P > 0.05) in global average protein 124 
microarray SI between groups within the uninfected and infected timepoints. Accordingly, to show 125 
the change in average antigen recognition between the uninfected and infected timepoints, the 126 
groups were pooled; all other analyses used unpooled data. For TC1 the average global protein 127 
microarray SI was: 1010 ± 21 (average ± SEM) for uninfected rat sera; 1632 ± 119 after the primary 128 
infection, a significant increase (Tukey HSD, P < 0.001); and, 2025 ± 113 after the secondary 129 
challenge infection (Tukey HSD, P < 0.001) (Figure 1B). The average number of highly reactive 130 
antigens, i.e. features with SI >50% of the most reactive IgG positive control, was 2.8 ± 1.2, 8.7 ± 131 
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1.1 and 26.6 ± 5.9 for the pre-, primary and secondary infection groups, respectively. TC2 (Figure 132 
1) had a similar pattern but with a lower overall SI, reflecting the raw SI (Supplementary Table 2) 133 
and shorter duration of this experiment. Uninfected samples had an average SI of 658 ± 13 134 
compared with 1275 ± 41 for infected sample groups (Figure 1C; t-test, P < 0.0001). The average 135 
number of highly reactive antigens was 1.5 ± 0.2 with pre-infection sera, and 9.2 ± 1.9, 7.4 ± 1.7 136 
and 11.2 ± 1.8 for I, I5 and I9 infection sera, respectively. 137 
To investigate the local tissue antibody response to schistosome antigens in the important sites of 138 
parasite elimination, the skin and lung, protein microarrays were screened with ASC probes and 139 
BAL fluid. Infected host skin and lung ASC probes were compared with control samples that 140 
included: other tissue antibodies (infected host liver and spleen ASC probes); the background lung 141 
response (infected host BAL fluid); and uninfected samples (uninfected host lung ASC probes) 142 
(Figures 1 and 3). The lower antibody titer ASC probes, as expected, had weaker SI compared to 143 
serum. The average SI for skin ASC probes was 490 ± 46 compared with 951 ± 121 for lung ASC 144 
probes and 550 ± 54 for the ASC control samples; the average number of highly reactive antigens 145 
was 1.4 ± 0.3, 5.8 ± 1.2 and 4 ± 2.4, respectively. Mouse sera following a 6 week schistosome 146 
infection were weakly reactive with nearly identical SI; 1068 ± 98 and 1064 ± 70, and averaged 147 
highly reactive antigens, 1.1 ± 0.1 and 3.2 ± 0.9, for the pre- and post-infection time points (Figures 148 
1 and 3, and Supplementary Figure 2).  149 
Antigens recognized by antibodies from infected hosts  150 
The top 40 rapid translation system (RTS) cell-free expressed recombinant protein antigens for both 151 
TC1 and TC2 (Figure 2), in order of the average SI for all the infection timepoints, included four 152 
S. mansoni and 36 S. japonicum proteins. Compared with rat samples, the SI for RTS antigens was 153 
much lower for the ASC probes and mouse samples and only the top 20 antigens are displayed in 154 
the heatmap (Figure 3); 18 S. japonicum and two S. mansoni RTS proteins were in the top 20. The 155 
top five TC1 and TC2 (Figure 2) and top ten ASC and MTC (Figure 3) in vivo expressed 156 
recombinant proteins and controls included dilutions of S. japonicum SjTSP2 (ABQ44513) 157 
expressed in yeast and bacteria, Sj phosphatase (AAP06500) and Sj silencer (AAP06461). These 158 
proteins were strongly recognized by all post-infection samples although there was reactivity in 159 
some pre-infection samples for Sj silencer (Figures 3 and 4). The in vivo S. mansoni expressed 160 
recombinants were less reactive but Sm annexin 1 (AAC79802) and Sm29 (AAC98911) were 161 
recognized by rodent sera following a primary or secondary infection. Sj silencer and Sj 162 
phosphatase were the only in vivo expressed recombinants proteins (Supplementary Table 5) that 163 
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strongly correlated with their RTS equivalents (Pearson’s r = 0.24 and 0.89, p = 0.025 and P < 164 
0.0001; n = 90).  165 
The top 25 RTS antigens for TC1 (Figure 4A) and TC2 (Figure 4B) were ranked using average SI 166 
and Benjamini-Hochberg adjusted (BH) P-values. Purely for graphing purposes, groups were 167 
pooled within timepoints for TC1 (Figure 4A). MTC (Figure 4C) and ASC probed (Figure 4D) 168 
microarrays were less reactive and therefore only 10 and 11 features, respectively, were selected, 169 
including in vivo recombinant proteins. In fact, only three RTS proteins were present within the 170 
reactive mouse set. There was considerable overlap between the samples with 38 proteins 171 
representing all the detected RTS antigens. Putative vaccine and diagnostic antigens were identified 172 
from the 38 detected RTS proteins by first excluding antigens if there was: less than 20% frequency 173 
of recognition within a sample group (8 proteins; Figure 4); or stronger recognition in pre-infection 174 
than post-infection sera (only Smp_194920, 46CF). The resulting 29 proteins were then categorized 175 
as putative novel vaccine and diagnostic candidate antigens (Table 1) or as associated with rodent 176 
schistosomiasis infection (Supplementary Tables 6 and 7). Vaccine antigens were selected by 177 
including antigens with high selection parameters (see Methods) that were not recognized by the 178 
mouse serum or had previously been tested for protective efficacy. 179 
 180 
The proteins associated with rodent infection included 17 S. japonicum (Supplementary Table 6) 181 
and four S. mansoni (Supplementary Table 7) antigens. The S. japonicum proteins included eight 182 
known tegument proteins, six had biological process ontologies (microtubule-based was the most 183 
common), and were most commonly found in the adult worm stage (8/17).
33
 The S. mansoni 184 
proteins had transport and metabolic biological process ontologies and were mainly recognized 185 
(4/4) by sera from the primary to early secondary infection (experiment TC2). The most prominent 186 
antigen recognized by all the samples was a hypothetical protein (AY815838). This antigen 187 
generally had the highest SI of all the antigens (pre-infection 2843 ± 132; post-infection: 29562 ± 188 
2770), and was often higher than the positive controls or in vivo recombinant proteins. The AUC 189 
values of the ROC plots for this antigen were a perfect 1.0 for all the rat sera (Figure 5), 0.8 for the 190 
ASC probes and 0.88 for the mouse sera (Table 1), and were equivalent or higher than in vivo 191 
recombinant SjTSP2, the next best antigen. Accordingly, AY815838 was chosen for future testing 192 
as a potential diagnostic antigen (SjDiag).  193 
Vaccine and therapeutic candidates recognized by rat serum and tissue antibodies 194 
Strikingly, 11 previously trialed vaccine antigens were amongst the proteins associated with rodent 195 
infection. In particular, antibodies to tegument antigens with dynein light chains, Sj21.7 196 
©    2015 Macmillan Publishers Limited. All rights reserved.
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(AF048759),
34,35
 Sj22.6 (L08198),
36,37
 Sj dynein light chain 1 (AF072327),
38,39
 Sm22.6 197 
(Smp_045200),
40,41
 and the related SjTAL12 (AY815113, similar to Sm22.6; 84% aa identity with 198 
TAL12
42
) were all present in infection rat sera and ASC probes. Other trialed vaccine candidates 199 
recognized exclusively by the rat included: SjGST-26 (M14654),
43
 Sj serpin B6 (AF380366),
44,45
 200 
Sjp40 major egg protein (AY814158),
46,47
 Sm filamin (Smp_000100),
48,49
 and the RTS expressed Sj 201 
phosphatase (AY223465)
3
 (Zhang, Li and McManus, QIMRB, unpublished data). However, the 202 
tetraspanin Sj23 (M63706),
50,51
 a known vaccine candidate, was also recognized by mouse infection 203 
sera. The remaining S. japonicum and S. mansoni antigens included hypothetical proteins, 204 
uncharacterized proteins and a potential therapeutic target (Smp_124240; Na/K transporting 205 
ATPase).
32,52
 Antigens reactive in skin and lung ASC samples were also recognized by serum 206 
samples; for example SjTSP2, SjDiag, Sj21.7 and a calponin-like protein (AY813467), closely 207 
related to the S. japonicum vaccine antigen,
53
 among others (Figures 4C and 4D). These findings 208 
suggest that antibodies against these antigens are generated by cognate B-cells in tissue-specific 209 
draining lymph nodes following parasite migration through the skin and lung.
26
 Notably, some of 210 
the antigens recognized by skin and lung ASC probes in our preliminary study
27
 were absent, 211 
reflecting the different samples used and the more stringent analyses applied in the current study. 212 
Putative vaccine and diagnostic candidate antigens 213 
In total, seven putative vaccine antigens and one diagnostic antigen were chosen for future testing 214 
(Table 1): three are specific to the schistosomes (tBLASTn expected value [E] < 10
-20
); half have 215 
transmembrane domains (4/8); and most have annotations or biological ontologies (6/8). Although 216 
four of the targeted antigens have not been detected in a previous shotgun proteomic study the 217 
remainder are found in the adult and/or schistosomule lifecycle stages
33
. The S. mansoni thioredoxin 218 
peroxidase 1 (SmTPx1, Smp_059480),
54
 was highly reactive with TC1 sera, and was also chosen as 219 
a putative vaccine antigen. This antigen, or potentially the S. japonicum homologue (tryparedoxin 220 
peroxidase, CAX71944), was included as a S. japonicum vaccine candidate because it had high 221 
protein microarray reactivity, is found in lung schistosomule excretory-secretory products, and is a 222 
protective S. mansoni vaccine.
55,56
 223 
Variation in antigen recognition over repeated infections in rat 224 
The two time courses, TC1 and TC2, with their overlapping data points allowed the examination of 225 
antigen recognition (Figures 5 and 6) from pre-infection to post-primary infection (4 and 6 weeks 226 
post-primary infection), to early post-secondary infection (6 weeks 5 days and 7 weeks 2 days post-227 
primary infection) and, finally, to late post-secondary infection (10, 12 and 14 weeks post-primary 228 
©    2015 Macmillan Publishers Limited. All rights reserved.
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infection). It must be noted that because of the different experimental conditions for each time 229 
course, comparisons could not be made of normalized SI between time courses; however, 230 
significant differences between pre-infection and post-infection timepoints within each time course 231 
were informative. The majority of reactive antigens belonged to three distinct profiles: consistent 232 
antigens, primary antigens and late secondary antigens.  233 
 234 
Antigens, such as those in the EF-hand and dynein light chain family (Sj22.6, Sj21.7, Sm22.6, and 235 
similar to Sm22.6/TAL12 protein) were recognized throughout the primary and secondary 236 
infections (Figure 6A) and were characterized as consistently reactive type antigens. These 237 
consistent antigens have low P-values and high AUC values, high SI fold change and high 238 
frequency of recognition values for most of the infection sera and ASC probes and also included the 239 
diagnostic antigen SjDiag and the in vivo recombinant proteins, SjTSP2 and SmTSP3. The second 240 
reactivity profile, primary antigens, are represented by SmTPx1, heat shock protein 86 (SjHSP86, 241 
AY815164) and a hypothetical protein with thrombospondin type 1 domain (SjTHBS1, AY809526) 242 
(Figure 6B). These primary infection antigens were strongly recognized following a primary 243 
infection. In particular, recognition of SjHSP86 was highly significant 4 weeks post-primary 244 
infection (P < 0.001) and it had an AUC value of 0.86 with the primary infection sera (Figure 5A) 245 
but was not reactive at other time points. SmTPx1 was also strongly recognized at late timepoints 246 
but not during the early secondary infection timepoints; hence its inclusion as a primary antigen.  247 
 248 
Late secondary antigens were recognized only 6 weeks after the secondary infection and increased 249 
with time. These proteins included Sj serpin B6 (AF380366), Sjp40 major egg protein (AY814158) 250 
and the discovered putative vaccine antigens, SjCutA (AY222951; similar to divalent cation 251 
tolerance protein) (Figure 6C), AY809178 (hypothetical guanylate kinase associated protein), Sj200 252 
(AY810129), AY815332 (coatomer subunit beta related) and Sj annexin 4 (AY223469). Notably, 253 
the late secondary antigen and a proposed diagnostic antigen,
47
 Sjp40, was an excellent indicator of 254 
late infection in this study (Figure 5B) and its recognition increased 24-27 days after infection 255 
coinciding with the onset of egg-laying.
57
 Furthermore, this antigen is highly abundant in the egg; 256 
the S. mansoni homologue, Smp40, is the third most abundant protein released from the egg.
58
 257 
Surprisingly, recognition of the egg antigen Sjp40 at the termination of TC1 and TC2 did not 258 
correlate with liver egg or granuloma burden (TC1: Pearson’s r = -0.21 and -0.15, p = 0.54 and 0.66, 259 
respectively, n = 11; TC2: Pearson’s r = 0.25 and 0.451, p = 0.361 and 0.09, respectively, n = 15). 260 
All the putative vaccine candidates, with the exception of the primary antigens SjTHBS1 and 261 
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SmTPx1, were late secondary antigens (Table 1 and Figure 4). However, pending further studies, it 262 
is not clear how these profiles relate to protective immunity or the selection of vaccine antigens. 263 
 264 
Discussion 265 
Humoral immunity is believed to be critical for elimination of the schistosome parasite by the 266 
host.
8,9,11,14
 However, the specific antigens, that are the target of this immunological attack, are 267 
mostly unidentified. Knowledge of these antigens is not just important for the immunobiology of 268 
schistosomiasis but specifically could be exploited for the discovery and development of vaccines 269 
and diagnostics. The rat has long been used as a model of immunological resistance for both 270 
S. japonicum
7,8,18,59
 and S. mansoni
10,11,15,60
 infection. Consequently, we screened serum and tissue 271 
antibodies from the rat using a protein microarray. We have described some of the parasite proteins 272 
that are recognized by rat serum and tissue antibodies, examined the antibody profile of the 273 
schistosomiasis susceptible mouse, explored the serological recognition of parasite-specific antigens 274 
during repeated infections in the rat, and prioritized a subset of detected antigens that may be 275 
efficacious as novel vaccines or diagnostics. 276 
 277 
In this study, and as previously observed,
7,8,18,19,61
 compared with the permissive mouse, rats had 278 
fewer adult worms, the worms present were severely stunted and egg production was drastically 279 
reduced. Furthermore, the liver egg burden, liver granuloma density and overall pathology were 280 
substantially reduced. In addition, very few viable eggs were retrieved from the liver. More 281 
importantly, the antibody profile for rats over the two time course experiments varied significantly. 282 
For example, anti-parasite serum antibody levels, determined by ELISA and the protein microarray, 283 
significantly increased following the primary and secondary challenge infections in the rat. 284 
Moreover, a similar anti-schistosome response is observed in S. japonicum-infected, self-curing 285 
rhesus macaques where there is a strong inverse association between the rapidity and intensity of the 286 
IgG response and the number and morphology of surviving worms.
62
 The mouse sera, on the other 287 
hand, had low protein microarray reactivity and recognized fewer features reflecting the increased 288 
susceptibility and weaker immune response in this animal model.
8,9,11,21
 289 
 290 
The skin- and lung-stage schistosomulum lifecycle stages are believed to be the most vulnerable to 291 
elimination by the host’s immune system9,15,16 thereby making larval-stage specific antigens 292 
attractive vaccine targets. Our previous work
26
 has shown that ASC probes from the skin- and lung-293 
draining lymph nodes of the rat were induced by the passage of migrating schistosome larval stages. 294 
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In addition, our earlier preliminary protein microarray study detected some the possible antigens 295 
recognized in the skin and lung immune compartments.
27
 We have extended this work and 296 
attempted to identify parasite protein antigens that are unique to these important sites of parasite 297 
elimination and immune priming. Compared with sera, the protein microarray SI was lower and the 298 
number of reactive antigens identified was less using the ASC probes. However, experiments with 299 
other parasites
63-65
 have similarly shown that ASC probes typically recognize a smaller and more 300 
specific set of antigens compared with serum. Reflecting the 10-fold difference in total antibody 301 
titers between the tissues,
26
 lung ASC probes recognized more antigens and had higher SI than the 302 
skin ASC probes. This may be the consequence of the higher antigenic load resulting from parasite 303 
elimination in the lungs, compared with the skin where larvae quickly transit through and fewer are 304 
killed, or alternatively the potentially greater immunogenicity of post skin-stage 305 
schistosomules.
21,66,67
 An alternative explanation for the differences in antigen recognition between 306 
skin and lung ASC probes could be the suppressed immune response of host skin exposed to 307 
schistosome larvae excretory/secretory products.
68,69
 Notably, several specific antibodies in sera 308 
(e.g. against SjTSP2, Sj21.7, Sj22.6, calponin-like and putative S. japonicum vaccine candidate 309 
TPx1), that were highly reactive and consistently detected over repeat infections, were also present 310 
in the lung ASC probes and, to a lesser degree, in skin suggesting that these two tissues are 311 
important immune priming sites for some anti-schistosome memory responses in the rat. ASC 312 
probes provide a source of antibodies that are specific to the local tissue of origin and when used in 313 
concert with antigen discovery platforms, such as the schistosome protein microarray, are able to 314 
identify the antigens that elicit immunological responses following local parasite migration. 315 
 316 
In an attempt to determine the temporal variation of parasite-specific antibody, rat sera were 317 
examined at several time points in the infectious cycle: prior to infection; after a primary infection; 318 
and finally after a secondary infection. As expected, antibody recognition of parasite proteins 319 
increased with repeated infections as the naïve host developed memory responses and was later re-320 
infected. We also observed that antigens were recognized in three apparent patterns (consistent, 321 
primary and late-secondary antibody responses) that likely relate to the manner by which the 322 
antigen is exposed to the host and the immunogenicity of the antigen. For example, egg antigens, 323 
which are highly antigenic,
4,58
 were, unsurprisingly, strongly recognized late in infection and 324 
coincided with the start of egg-laying. In addition to Sjp40, Serpin B6, a serine protease inhibitor 325 
that is predominantly expressed in the egg,
45
 was another late-secondary antigen. However, the 326 
current protein microarray includes only a subset of the complete schistosome proteome with a 327 
number of immunogenic proteins, such as those from the egg lifecycle stage, being absent. Future 328 
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studies using more comprehensive schistosome protein microarrays that include more egg lifecycle 329 
stage specific antigens may help to further elucidate the role of egg products in pathology and 330 
resistance in the rat and mouse.  331 
 332 
Notably, consistently strong responses throughout the infection were found for tegument allergen-333 
like proteins (TAL), Sj22.6, Sj21.7, Sm22.6 and SjTAL12.
42
 These immunogenic TAL proteins 334 
have conserved dynein light chain sequences with one or two EF-hand motifs and several known 335 
IgE epitopes. In particular, high anti-Sm/Sj22.6 and anti-Sm/Sj21.7 antibody levels are common in 336 
human S. mansoni and S. japonicum endemic populations.
70-73
 Dunne and colleagues have noted 337 
that age/drug-related human resistance is associated with high anti-Sm22.6 IgG1 and IgE levels. 338 
They have proposed that antibodies to Sm22.6 spike after drug treatment when the protein is 339 
released from dying worms while Sm21.7 is constantly released from eggs and becomes 340 
immunologically tolerised.
42,70,72
 Similarly, Sj21.7 is highly expressed across most lifecycles stages 341 
and is found at the protein level in all stages; Sj22.6 is transcriptionally upregulated in the adult 342 
male and has been detected proteomically in the adult and schistosomulum.
33,74
 Given the homology 343 
between these identified TAL-like proteins and the presence of conserved domains in the sequences 344 
it is not clear if rat antibodies are cross-reactive or specific for all of the detected TAL-like antigens. 345 
Nonetheless, these four S. japonicum and S. mansoni TAL-related proteins may hint at a shared 346 
resistance mechanism between rats and humans.
9
 347 
 348 
The Schistosoma protein microarray proved to be an excellent screening tool for antigen discovery. 349 
Encouragingly, previously well studied antigenic and protective molecules were recognized. 350 
However, antibody recognition by the resistant rat host does not assure vaccine-induced protective 351 
immunity. For example, highly antigenic “bystander” proteins exposed during parasite death or egg-352 
laying may also stimulate high antibody titers. In contrast, non-detection during protein microarray 353 
screening of an antigen does not imply immunological irrelevance. Indeed, the cell-free RTS 354 
proteins, used for fabricating the protein microarray, lack the translational modifications and 355 
disulfide bonds found in native proteins and therefore some epitopes may be absent.
22,32
 Yet, the 356 
relatively small number of proteins identified (29) and the high proportion of previously trialed 357 
vaccine antigens and therapeutic targets (12), including highly protective vaccines, within this set 358 
implies that there are potentially protective vaccine candidates among the untested proteins.  359 
 360 
Potentially, the most important finding from this study was the discovery of seven new putative 361 
vaccine candidates and one potential diagnostic. These antigens include a mixture of hypothetical 362 
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and well annotated proteins. Six of the candidates (Sm/SjTPx1, AY809178, SjHSP86, Sj200, Sj 363 
Annexin 4 and SjDiag) have been detected in the proteomes of cercariae, schistosomula or adult 364 
worms, four have signal peptides and/or transmembrane domains (SjTHBS1, Sj200, SjCutA and 365 
SjDiag), and three have high sequence homology only within the schistosome species (AY809178, 366 
SjTHBS1 and Sj200). Importantly, these are novel proteins that have not been studied as S. 367 
japonicum vaccines or diagnostics. Further research into these proteins could include mouse vaccine 368 
trials (manuscript in preparation), diagnostic screening of endemic human populations, and, 369 
considering that most transmission of S. japonicum is via water buffalo,
75
 bovine vaccine field trials. 370 
 371 
In conclusion, screening of the schistosome protein microarray allowed for the simultaneous 372 
comparison of hundreds of parasite proteins for host antibody specificity and reactivity. This 373 
revealed patterns in parasite-host immunity, and led to the discovery of potential diagnostic and 374 
vaccine antigens. The use of ASC probes for antibody screening of protein microarrays has proven 375 
to complement serological antigen discovery and to also help elucidate immune mechanisms in 376 
experimental schistosomiasis. Importantly, using resistant and susceptible rodent antibodies from 377 
sera and tissue-specific lymph nodes, that were probed on the schistosome protein microarray, a set 378 
of 29 differentially reactive antigens were identified that were prominent in the resistant rat animal 379 
model. Within this set are well characterized antigens that have been previously trialed as 380 
schistosome vaccines and therapeutic agents, as well as seven novel vaccine candidates and one 381 
diagnostic antigen, all of which are untested and largely uncharacterized proteins. 382 
Methods 383 
Experimental infections and biological sample collection 384 
For the first rat time course, TC1, four groups of 8-12 week old Wistar rats (n=4; Animal Resource 385 
Centre, Western Australia) were used. Three groups of rats (T4, T6 and T8) were infected for four, 386 
six and eight weeks, respectively, with 200 cercariae per rat and challenged with an additional 200 387 
cercariae per rat before termination six weeks later. One group, the negative control, was not 388 
infected but samples were collected for serological and histological comparison (data not shown). 389 
Similarly, during the second time course, TC2, four groups of 8-12 week old Wistar rats (n=5; 390 
Animal Resource Centre) were used. As in the previous time course, samples were collected from a 391 
negative control group for comparison with the other groups in the time course (data not shown). 392 
The three other groups (I, I5 and I9) were given a primary infection of 125 cercariae per rat for six 393 
weeks. After this group I was terminated while groups I5 and I9 were challenged with 350 cercariae 394 
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per rat and terminated five and nine days later, respectively. The time points in TC1 were based on 395 
observations that immune resistance in the rat has been shown to be highest between 4-8 weeks 396 
after re-infection.
19,60
 The time points in TC2 were selected to capture the local tissue response after 397 
schistosome larval migration though the skin and lung after the first and fourth day post-infection, 398 
respectively,
19
 and after allowing a further five days for an optimal lymph node response.
26,27,63
 The 399 
cercarial challenge load for TC1 was determined from previous studies
8,19
 and from preliminary 400 
experiments for TC2;
26
 specifically the higher cercarial challenge for the second infection in TC2 401 
ensured that skin- and lung-draining antibody secreting cells were adequately stimulated. For both 402 
TC1 and TC2 blood was collected prior to the primary and secondary infections and during 403 
termination. Equivalent time points were collected for the control groups in both rat time courses. 404 
Similar to previous studies
8,19,59,61
 we used outbred rats to better model the host heterogeneity found 405 
in schistosome-endemic animal and human populations. Blood was collected during the time course 406 
and at necropsy. A mouse time course experiment (MTC) was also completed. As with the rat, an 407 
outbred mouse strain was used for serological protein microarray probing. Eight to twelve-week old 408 
female outbred Swiss strain mice (n = 9; Animal Resource Centre) were infected with at least 70 409 
cercariae and blood was collected the day prior to infection and 6 weeks post-infection. The Swiss 410 
mice were perfused to confirm schistosome infection and liver pathology. CBA mice (n = 10; 411 
Animal Resource Centre), one of the mouse strains typically used in schistosome immunology 412 
studies, were infected with 34 cercariae for six weeks for histological staining and parasitological 413 
burden measures. 414 
 415 
S. japonicum (Chinese strain; Anhui province field isolate) cercariae were shed from infected 416 
Oncomelania hupensis hupensis snails after 3-4 hours of fluorescent light exposure. The cercariae 417 
were collected with loops, counted using a dissecting microscope, and transferred to microscope 418 
cover slips for experimental infections. Rats and mice were challenged subcutaneously with freshly 419 
shed cercariae via shaved abdominal skin for 30-40 min using the cover slip method. Rats were 420 
anaesthetized with gaseous isofluorine or IP injection of pentobarbitone (30 mg/kg) and euthanized 421 
with IP Lethabarb (Virbac, Reagents Park, Australia). Mice were anaesthetized with IP ketamine 422 
(100 mg/kg) and xylazil-20 (30 mg/kg) and euthanized by CO2 inhalation. Blood was collected via 423 
the tail vein (for rats), tail tip (for mice) or from cardiac puncture at necropsy. The blood samples 424 
were allowed to coagulate at 4˚C for 1 hour and the sera were collected by centrifuging (10 min at 425 
16 000 x g and 4˚C). Sera were stored at -80˚C until use. After four weeks post-infection, mouse 426 
and rat faces were collected periodically to confirm the presence and viability of schistosome eggs. 427 
An aliquot of fresh faces was checked using the miracidial hatching test (MHT).
76
 The aliquot was 428 
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homogenized in unchlorinated filter water and the sediment rinsed twice. The sediment was mixed 429 
with water and left at RT in a glass flask illuminated at the neck with a lamp. The flask was checked 430 
periodically over 24 hours for the presence of miracidia.
77,78
 At necropsy the animals were perfused 431 
through the portal vein, the worms were rinsed in perfusion buffer, fixed in neutral buffered 432 
formalin (NBF: PBS buffered with 4% (v/v) formaldehyde).
72,73
 During rat necropsies, the liver and 433 
lungs were dissected out, rinsed with perfusion buffer and a lobe of each was fixed in NBF 434 
overnight and stored in 70% (v/v) ethanol. The remainder of the liver was stored on ice for egg 435 
burden counts. Both the fixed liver lobe and remaining liver were weighed prior to storage. A 436 
sample of the fresh liver was chopped and processed as described above for the MHT. During TC2, 437 
additional samples were taken. Bronchoalveolar lavage (BAL) fluid was collected to determine the 438 
lung response, by washing the lungs with 1 ml PBS using a drawing up needle and syringe. The 439 
spleen, abdominal skin-draining (axillary and inguinal), lung-draining (mediastinal), and liver-440 
draining (portal) lymph nodes (LN) were also dissected out. The livers of perfused mice were 441 
dissected out and processed as above. All animal experiments were approved by and performed 442 
according to the guidelines of the QIMR Animal Ethics Committee (project P288). 443 
 444 
Parasite burden, histology and antibody secreting cell (ASC) probe preparation 445 
The lengths of fixed worms were measured from digital images (Leica MZFL stereo microscope) 446 
using ImageJ software (version 1.45, National Institutes of Health, USA).
77
 The lung lobes and one 447 
lobe of the liver were fixed in 10% formalin in neutral phosphate buffered saline, embedded in 448 
paraffin for sectioning, and stained with hematoxylin and eosin (H&E). Digital images of the 449 
stained slides were prepared (Aperio XT whole slide scanner, Aperio, USA) and the granuloma 450 
density was measured using the point counting method with ImageJ software, as previously 451 
described.
77
 The average of five randomly selected snapshots was used to determine the granuloma 452 
burden. The liver egg burden was measured by digesting the remaining liver for 20 hours in 5% 453 
(w/v) potassium hydroxide at 37˚C.79 The solution was centrifuged at 1000 rpm for 10 min; the 454 
pellet was washed and resuspended in 1 ml NBF. The liver egg burden was measured by counting, 455 
at 40x magnification, numbers of eggs in three 5 µl aliquots and using the average to calculate the 456 
eggs per gram of liver (liver EPG).  457 
 458 
ASC probes were prepared as previously described.
26
 Briefly, LNs were aseptically teased apart 459 
with forceps into media supplemented with fetal bovine serum [RPMI+FCS: RPMI + L-glutamine 460 
with 5% (v/v) fetal bovine serum, penicillin (100 U/ml) and streptomycin (100 µg/ml) (Gibco, 461 
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Carlsbad, USA)] and washed twice in cold media. Viable cells were counted with trypan blue dye 462 
and a haemocytometer, resuspended to a density of 3 x 10
5
 cells/ml in media supplemented with 0.1 463 
ng/ml recombinant rat interleukin-6 (IL-6; R&D Systems, Minneapolis, USA), and then incubated 464 
for five days at 37˚C and 5% CO2. Cultures were centrifuged at 500 x g for 8 min at 4˚C and the 465 
supernatant stored at -20˚C.  466 
 467 
Protein microarray immunoscreening 468 
Schistosome protein microarrays were produced as described.
23,25,32
 From published S. japonicum 469 
and S. mansoni transcriptomic and proteomic databases
33,80,81
 a subset of 214 S. japonicum and 63 470 
S. mansoni putatively immunogenic protein-coding sequences was selected. Sequence inclusion was 471 
based on known/predicted tegument surface location, high sequence conservation between 472 
S. japonicum and S. mansoni, expression in the larval schistosomulum lifecycle stage, and low 473 
sequence homology with mammalian hosts.
25,32
 Sequences were PCR amplified, using homologous 474 
recombination, cloned into the pXi expression vector, and quality checked using PCR and plasmid 475 
sequencing.
22,23
 Two hundred and twenty two (172 S. japonicum and 50 S. mansoni) high quality 476 
sequences were selected (Supplementary Table 2) for expression in a cell-free system (RTS) (RTS 477 
100, Roche, Germany). The unpurified protein extracts were contact printed (Omnigrid, Digilab, 478 
USA) onto nitrocellulose slides (FAST, Whatman, UK). In addition, negative controls (No DNA 479 
controls: RTS lysate containing no plasmid DNA; PBS only; and blank spots), positive controls 480 
(IgG control: purified immunoglobulin; and Epstein-Barr nuclear antigen [EBNA-1]), as well as 481 
comparison controls, consisting of recombinant bacterial- and yeast-expressed S. japonicum and 482 
S. mansoni proteins with known immunogenicity, were printed on the protein microarrays.
25,32
 The 483 
expression efficiency of printed RTS proteins was checked by probing for the presence of N-484 
terminal 10xHis and C-terminal hemagglutinin (HA) tags; over 97% RTS proteins were detected by 485 
anti-His and/or anti-HA antibodies.  486 
 487 
The protein microarrays were probed with mouse sera and rat BAL fluid, sera and ASC probes and 488 
IgG reactivity measured. As a consequence of variations in aims, different samples were used and a 489 
more rigorous probing and analysis strategy was applied compared to our preliminary protein 490 
microarray ASC study.
27
 BAL fluid and ASC probes had lower antibody titers than sera with 491 
reactivity being at least 100 fold lower for the ASC probes
26,27
 and 50 fold lower for BAL fluid 492 
(data not presented), and they were therefore used at lower dilutions (1:2 and 1:10, for ASC probes 493 
and BAL fluid respectively, compared with 1:100 for sera). Moreover only ASC probes with high 494 
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antibody titers were used for the microarray experiments. As a result a total of four individual skin 495 
ASC probes (three from I5 and one from I9) with the highest antibody titers and one pooled sample 496 
of the remaining ASC probes were used. Likewise for lung ASC probes, four individual samples 497 
(one from I5 and three from I9) and a pooled sample were used. For comparison, pooled (four from 498 
I9) liver, pooled (five from I9) spleen and individual control lung ASC probes and pooled (five from 499 
I9) BAL fluid were tested on the protein microarray. BAL fluid, liver, spleen and control ASC 500 
probes were used as controls to better enable selection of antigens specific to the skin and lung 501 
tissue compartments. All samples were diluted accordingly in blocking buffer (Whatman, 502 
Maidstone, UK), and mixed at room temperature (RT) with gentle rocking for 30 min with 10% 503 
(w/v) E. coli lysate (MC Lab, San Francisco, USA). Protein microarray slides, pre-hydrated in 504 
blocking buffer for 30 min at RT, were probed with diluted sera, BAL fluid or ASC probes 505 
overnight at 4°C with gentle rocking. After three sets of 5 min washes with 0.05% Tween 20 in TBS 506 
(TBST), IgG-detecting secondary antibody conjugated to biotin (1:1000 in blocking buffer) was 507 
incubated for 1 hour at RT. The secondary antibodies used were goat anti-rat IgG (whole molecule) 508 
biotin-conjugated (Sigma Aldrich, St Louis, MO, USA) and goat anti-mouse IgG (Fc specific) 509 
biotin-conjugated (Jackson Immunoresearch Laboratories, West Grove, PA, USA). After washing, 510 
the protein microarrays were incubated with streptavidin Cy5 (Surelight P3, Columbia Biosciences, 511 
Columbia, USA) for 1 hour at RT. After a final washing step with TBST, TBS and water each three 512 
times for 5 min, the protein microarrays were air dried in the dark and scanned with a Genepix 513 
4300A scanner (Molecular Devices, Sunnyvale, USA). The signal intensities (SI) for all IgG 514 
reactivity were measured at a laser setting of 100% and PMT of 600. These settings were found to 515 
provide the highest signal to noise ratio for the majority of the probed samples. 516 
 517 
Data analysis 518 
Protein microarray feature data were pre-processed and analyzed as described
27,32
 but with some 519 
modifications. The raw SI was generated after local background correction of protein microarray 520 
features. In addition, to account for reactivity in the RTS lysate, the mean of the “No DNA” features 521 
was subtracted from the raw SI within each microarray. These data were transformed and 522 
normalized using the variance stabilizing normalization algorithm
82
 in the vsn R package (R project 523 
for statistical computing, www.r-project.org; www.bioconductor.org). The normalized data were 524 
then analyzed further or retransformed (inverse log2) to a relative SI for graphs and heat maps. The 525 
average SI across all the protein microarray features (global SI) was used to compare the change in 526 
total protein microarray reactivity during the experimental time course and between tissue regions. 527 
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Seropositive antigens were defined as having an SI greater than the average plus four standard 528 
deviations (SD) of the “No DNA” controls within each microarray. This high positivity threshold 529 
was used to more stringently identify reactive antigens for putative vaccine and diagnostic 530 
selection.
32,83
  531 
 532 
The Cyber-T package (http://cybert.ics.uci.edu/), also written in the R language, used extensively 533 
for analysis of protein and nucleic acid microarrays,
83-85
 was employed to generate Bayesian-534 
adjusted t-test and ANOVA results and multiple hypothesis testing correction of resulting P-values. 535 
Bayesian standard deviation estimation corrects for low replication within treatment groups, usually 536 
inherent in microarray data, by estimating the variance from similar SI within each microarray and 537 
calculating the regularized t-test and ANOVA.
84
 For larger datasets, typically with thousands of 538 
microarray features, non-specific filtering of unchanged features is required to control false 539 
positives following multiple comparisons.
86
 However, the schistosome protein microarray contains 540 
only 289 features; therefore all the data were used without pre-filtering and the false discovery rate 541 
(FDR) was controlled using the Benjamini and Hochberg (BH) correction within the Cyber-T 542 
package.
84
 Significant BH-corrected ANOVA P-values were then subjected to testing with pairwise 543 
post-hoc t-tests (Tukey HSD) to identity differentially reactive features between groups. To further 544 
identify differentially reactive antigens between comparison groups the area under the curve (AUC) 545 
was calculated for receiver operating characteristic curves (ROC; R package, 546 
www.bioconductor.org). ROC curves plot the false positive rate (1 - specificity) against the true 547 
positive rate (sensitivity) and measure the ability of an antigen to differentiate between two groups 548 
where a value close to 1 is a good prediction and 0.5 to 0 is poorly predictive.  549 
 550 
Based on the average SI and BH P-values, the top RTS proteins were chosen for further analysis. 551 
From this set of top RTS proteins those with < 20% frequency of recognition (percentage of 552 
seropositive individual samples within a group) or were more strongly recognized pre-infection 553 
compared to post-infection were excluded. Selection parameters (BH P-value, AUC value, SI fold-554 
change and frequency of recognition) were used to categorize RTS proteins. Putative novel S. 555 
japonicum vaccine candidates were selected by: including antigens with high selection parameters 556 
in post-infection rat sera and ASC probes; removing antigens that had been previously tested as 557 
vaccines or therapeutics; or were associated with infection in the mouse using the above criteria. 558 
The remaining antigens were defined as proteins associated with rodent schistosomiasis infection. 559 
Diagnostic antigens were selected on the basis of high reactivity in all infection samples. Gene 560 
ontologies (http://www.geneontology.org) and protein details were retrieved using the BLAST2GO 561 
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program (www.blast2go.com). Statistical analysis between groups for ELISA immunoglobulin 562 
levels and protein microarray global SI were completed using t-tests or ANOVA and Tukey HSD 563 
post-hoc t-test pair-wise testing (GraphPad Prism 5, San Diego, CA, USA). 564 
 565 
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Appendices 899 
Supplementary Figure 1: Rat pathology is reduced compared with that in the mouse after 900 
S. japonicum infection. Haematoxylin and eosin (H&E) staining of sectioned formalin-fixed 901 
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paraffin-embedded: typical appearance of infected rat liver (A); typical appearance of infected 902 
mouse liver (B); and infected rat lung (C). The rat liver has a small granuloma (arrow) following a 903 
primary infection and termination 6 weeks later (TC2 – I). The mouse liver is characterized by large 904 
granulomas with numerous eggs (arrows) following infection and termination 6 weeks later. Three 905 
lung stage schistosomules (arrows) are shown in the rat lung following primary infection, secondary 906 
challenge 6 weeks later and termination after 9 days (TC2 – I9) (200 µm scale bar on images).  907 
 908 
Supplementary Figure 2: Schistosome protein recognition by host antibodies increases with 909 
infection frequency and is consistent within treatment groups but varies between host species. 910 
The schistosome protein microarray after probing with serum: from an individual rat (T4-1) prior to 911 
infection (A), four weeks after a primary infection (B) and six weeks after a secondary infection; 912 
from a treatment group 8 weeks after a secondary infection for rats T8-2 (D), T8-3 (E), and T8-4 (F); 913 
and from a representative mouse prior to infection (G) and 6 weeks after infection (H). Note the 914 
grayscale representation used here emphasizes strongly recognized protein antigens. 915 
 916 
Supplementary Table 1: Parasitological measurements of rats from time courses 1 (TC1) and 917 
2 (TC2). TC1 used three different intervals between the primary and secondary infection (200 918 
cercariae/rat/infection): group T4 with 4 weeks; T6 with 6 weeks; and T8 with 8 weeks. TC2 used 919 
three groups, all with a primary infection (125 cercariae/rat) for six weeks and followed by a 920 
secondary infection for groups I5 and I9 (350 cercariae/rat). Group I was sacrificed six weeks after 921 
the primary infection; groups I5 and I9 were sacrificed 5 and 9 days after the secondary infection, 922 
respectively. 923 
 924 
Supplementary Table 2: Composition of the schistosome protein microarray (XLSX). The 925 
features of the schistosome protein microarray including control features, in vivo recombinant 926 
proteins and RTS expressed proteins. The dilutions, annotations, accession numbers and protein 927 
characteristics are included as applicable. 928 
 929 
Supplementary Table 3: Raw signal intensities for protein microarrays probed with rodent 930 
antibodies (XLSX). The un-normalized signal intensities for protein microarray features probed 931 
with 90 rodent serum and tissue-specific antibodies.  932 
 933 
Supplementary Table 4: Normalized signal intensities for protein microarrays probed with 934 
rodent antibodies (XLSX). The normalized signal intensities (SI) for protein microarray features 935 
©    2015 Macmillan Publishers Limited. All rights reserved.
27 
 
probed with 90 rodent serum and tissue-specific antibodies. The raw SI was VSN normalized. For 936 
visualization purposes the VSN-normalized data was inverse log2 transformed. The VSN-937 
normalized data were analyzed using a Bayesian regularized ANOVA with post-hoc pairwise 938 
Tukey HSD t-test comparisons. The P-values were adjusted for multiple testing using the Benjamini 939 
and Hochberg (BH) correction. The frequency of recognition within each group was calculated for 940 
each protein microarray feature. 941 
 942 
Supplementary Table 5: Pearson correlations of rodent sample reactivity to cell-free (RST) 943 
and in vivo recombinant proteins (DOCX). Pearson R values and statistical significance were 944 
calculated for the correlations between RTS and in vivo recombinant antigens on the schistosome 945 
protein microarray after probing with 90 rodent serum and tissue-specific antibodies. 946 
 947 
Supplementary Table 6: S. japonicum antigens on the schistosome protein microarray 948 
associated with rodent infection. Antigens were selected by Benjamini-Hochberg adjusted P-949 
values between pre-infection and post-infection samples from rat time course one (TC1) and two 950 
(TC2), mouse (M) and ASC (A) sample probing.  951 
 952 
Supplementary Table 7: S. mansoni antigens on the schistosome protein microarray 953 
associated with rodent infection. Antigens were selected by Benjamini-Hochberg adjusted P-954 
values between pre-infection and post-infection samples from rat time course one (T1) and two 955 
(T2), mouse (M) and ASC (A) sample probing. 956 
 957 
 958 
Figure Legends 959 
Figure 1: Schistosome protein microarray probed with rat and mouse antibody samples.  A: 960 
Raw signal intensities (SI) were normalized with the vsn R package, retransformed (inverse log2) 961 
and displayed in a heatmap. Protein microarray features are in rows (21 Controls include IgG 962 
positive controls and “No DNA” negative controls; 46 in vivo recombinant proteins include 963 
dilutions of 20 proteins and 222 cell-free (RTS) proteins (Supplementary Table 2) and biological 964 
samples are in columns (TC1: rat time course 1, n = 28; TC2: rat time course 2, n = 30; ASC: 965 
antibody secreting cell probes, n = 14; MTC: mouse time course, n = 18). The sample groups are 966 
labelled (Pre: pre-infection; Inf: infected; Prim: primary infection; and Sec: secondary infection; 967 
Ctrl: control, liver, spleen ASC; Skin: skin-draining lymph node ASC; and Lung: lung-draining 968 
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ASC). The features were ranked in decreasing order by the average SI. The color scale indicates the 969 
normalized SI. Scatter plot of normalized SI for TC1 (B) and TC2 (C). ANOVA and t-test 970 
significance are displayed on the graph (** P < 0.001, *** P < 0.0001). 971 
 972 
Figure 2: Heat map of the schistosome protein microarray reactive antigens and controls from 973 
rat time course 1 (TC1) and 2 (TC2). Raw signal intensities (SI) were normalized (vsn), 974 
retransformed (inverse log2) to a relative signal intensity and averaged within each group at each 975 
time point (Pre: pre-infection; Inf: infected; Prim: primary infection; and Sec: secondary infection). 976 
The antigens are in decreasing order by the average SI and the top 40 cell-free (RTS) proteins and 977 
top five in vivo recombinant proteins are displayed along with “No DNA” negative controls 1 and 2. 978 
The color scale indicates the normalized signal intensity. RTS proteins include the accession 979 
number, feature name in brackets (PD code for S. japonicum and CF code for S. mansoni), and 980 
additional annotation. In vivo proteins include the construct name, expression host and dilution 981 
number (see Supplementary Table 2). 982 
 983 
Figure 3: Heat map of the schistosome protein microarray reactive antigens from rat 984 
antibody secreting cell (ASC) probes and mouse infection sera (MTC). (From previous page) 985 
Raw signal intensities were normalized with the vsn package and retransformed (inverse log2) to a 986 
relative signal intensity. The antigens were ranked in decreasing order by the average of the skin 987 
and lung ASC probes and infected mouse sera. The top 20 cell-free (RTS) proteins and top 15 988 
in vivo recombinant proteins are displayed along with “No DNA” negative controls 1 and 2. The 989 
color scale indicates the signal intensity. RTS proteins include the accession number, feature name 990 
in brackets (PD code for S. japonicum and CF code for S. mansoni), and additional annotation. In 991 
vivo proteins include the construct name, expression host and dilution number (Supplementary 992 
Table 2). Probed samples: Ctrl: control samples; Neg: control rat 2 lung ASC probes; Liver: pooled 993 
I9 liver ASC probes; Spleen: pooled I9 spleen ASC probes; BAL: pooled I9 BAL fluid; Skin: skin 994 
ASC probes; Lung: lung ASC probes; and MTC: Swiss mouse uninfected and after schistosome 995 
infection (6 weeks) individuals (1-9). 996 
 997 
Figure 4: Average signal intensity and P-value of the top rodent antigens on the schistosome 998 
protein microarray. The average signal intensity (columns with standard error of the mean bars) 999 
and Benjamini-Hochberg adjusted P-values (yellow line) for rat time course 1, TC1 (A), time 1000 
course 2, TC2 (B), mouse time course MTC (C) and antibody secreting cell (ASC) probe screening 1001 
(D). The rat and mouse sera samples probed were: pre-infection (Pre), primary infection (Prim), 1002 
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secondary infection (Sec), group I (I), group I5 (I5) and group I9 (I9). ASC probes were derived from 1003 
infected rat lung- and skin-draining lymph nodes (LN) and the control (Ctrl) samples were from 1004 
infected liver, spleen-LN and uninfected control lung-LN ASC probes, and bronchoalveolar lavage 1005 
(BAL) fluid from infected rats. In vivo expressed recombinant proteins for experiments one and two 1006 
are not displayed. Previously tested (T) vaccines and putative vaccine (V) antigens are marked in 1007 
the figure. BH P = 0.05 is displayed as a dashed line on the graph. Antigens with low frequency of 1008 
recognition (< 20%) within a sample group are marked (#). 1009 
 1010 
Figure 5: Receiver operating characteristic (ROC) curves of antigens recognized by rat 1011 
serum. ROC curves for time course 1 (TC1) primary infection (A); secondary infection (B); and 1012 
time course 2 (TC2) post-infection (C) rat sera are displayed. The area under the curve (AUC) value 1013 
is calculated from the ROC curve. The diagnostic antigen, SjDiag (AY815838) has a perfect AUC 1014 
of 1 in all graphs. Heat shock protein 86 (SjHSP86, AY815164) and Sjp40 major egg antigen 1015 
(AY814158) are good diagnostics of primary (0.89) and secondary infection (0.96), respectively. A 1016 
value of AUC 0.5 is shown as reference (thin solid blue). 1017 
 1018 
Figure 6: Reactivity of selected antigens during the rat time course (TC1 and TC2) 1019 
experiments. The reactivity profiles of: consistently reactive type antigens, Sj22.6 (L08198), Sj21.7 1020 
(AF048759), Sm22.6 (Smp_045200) and SjTAL12/similar to Sm22.6 (AY815113) (A); primary 1021 
infection reactive type antigens, SmTPx1 (Smp_059480; thioredoxin peroxidase 1), SjTHBS1 1022 
(AY809526; hypothetical, thrombospondin type 1 domain) and SjHSP86 (AY809526; heat shock 1023 
protein 86, (B); and late secondary infection reactive type antigens, Sj serpin B6 (187PD257), Sjp40 1024 
major egg protein (AY814158) and SjCutA (AY222951; similar to divalent cation tolerance 1025 
protein) (C). Each column (error bars are standard error of the mean) is the average normalized 1026 
signal intensity of sera collected at the time points in weeks during time course 1 (TC1) and 2 1027 
(TC2). Antigens are identified in the legend. The significance values of each time point compared 1028 
with pre-infection sera are marked (Tukey HSD post-hoc pairwise t-test: * P < 0.05; † P < 0.001; ‡ 1029 
P < 10
-4
). 1030 
 1031 
 1032 
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Table 1: Putative vaccine and diagnostic antigens on the schistosome protein microarray selected after rodent sample probing.  
Accession 
Number  
ID 
Annotation 
(BLASTp % amino acid 
identity)
$ 
Signal intensity fold change 
AUC value 
Frequency of recognition (%)
© 
Proteomic Information 
Putative 
Diagnostic/ 
Vaccine 
Rat 
Mouse 
Protein/ 
fragment 
length 
Signal 
Peptide
 
Transmem 
domains
 
Lifecycle 
Stage
# 
Schisto. 
Specific 
Biological Process  
Gene Ontology (GO)
 
Prim 
Early 
Sec. 
Late 
Sec. 
ASC 
Skin Lung 
Smp_059480 
2CF 
SmTPx1 , Thioredoxin 
peroxidase 1, (82% aa Sj 
AAW27020; 72% aa 
Sj22.6) 
7.2 
0.89 
55% 
1.2 
0.84 
30% 
16.6 
0.94 
91% 
0.1 
0.70 
0% 
2.1 
0.66 
40% 
1.1 
0.51 
0% 
185 n - SE
† 
n 
cell redox 
homeostasis
 Vaccine
25,26
 
AY809178 
54PD110  
Hypothetical/ 
guanylate-kinase-assoc. 
(61% aa Sm CCD75025) 
3.1 
0.89 
27% 
0.9 
0.56 
0% 
8.9 
0.93 
100% 
0.5 
0.65 
0% 
0.5 
0.65 
0% 
1.1 
0.54 
0% 
291 n - SAM y Cell-cell signalling Vaccine 
AY809526 
80PD136 
SjTHBS1, hypothetical/ 
thrombospondin type 1 
5.9 
0.54 
27% 
2.7 
0.64 
40% 
2.1 
0.76 
27% 
0.9 
0.63 
60% 
1.2 
0.56 
80% 
1.2 
0.60 
0% 
121 n 1 S y  Vaccine 
AY810129 
108PD169 
Sj200, sim. surface 
protein (70% aa Sm200 
GPI-anchored / 31CF) 
1.0 
0.56 
27% 
0.6 
0.66 
40% 
3.1 
0.80 
64% 
0.8 
0.76 
0% 
1.1 
0.49 
40% 
0.9 
0.62 
11% 
238 n 1 A y  Vaccine
30
 
AY815332 
159PD225 
Coatomer subunit beta 
(63% aa Cs coatomer) 
1.6 
0.61 
0% 
1.6 
0.78 
10% 
3.2 
0.83 
27% 
0.6 
0.70 
0% 
1.1 
0.60 
0% 
1.0 
0.54 
0% 
162 n - - n 
vesicle-mediated 
transport; protein 
complex assembly 
Vaccine 
AY222951 
195PD269 
SjCutA (85% aa Sm 
divalent cation 
tolerance Cut A 
XP002576196) 
1.3 
0.64 
27% 
0.7 
0.66 
40% 
12.1 
0.96 
82% 
1.5 
0.78 
80% 
1.3 
0.66 
100% 
1.3 
0.67 
22% 
130 y 2 - n 
response to metal 
ion 
Vaccine 
AY223469* 
204PD278 
Sj Annexin 4 (80% aa Sm 
annexin XP002575877) 
2.2 
0.63 
18% 
1.5 
0.54 
20% 
8.9 
0.9 
55% 
0.3 
0.63 
0% 
0.3 
0.65 
0% 
1.1 
0.58 
0% 
330 n - CA n calcium ion binding Vaccine
31,32
 
AY815838 
170PD239 
SjDiag, Hypothetical 
15.1 
1.0 
100% 
13.0 
1.0 
100% 
15.0 
1.0 
100% 
0.2 
0.80 
100% 
2.2 
0.78 
100% 
3.9 
0.88 
100% 
120 y 2 CA n  Diagnostic 
Proteomic and biological ontology information from 
26
 and BLAST2GO (www.blast2go.com). 
#
 Protein lifecycle stage expression for cercaria 
(C), schistosomulum (S), adult (A), egg (E) and miracidium (M). Homologues: 
†
SJCHGC02884 (AAW27020), 
*
SJCHGC02020 (AAW27836). 
$
 S. japonicum or S. mansoni BLASTp identity with expected value < 10
-50
. Prim: primary time points TC1 and group I / TC2; Early Sec: groups 
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I5 and I9; and Late Sec: secondary time points TC1. 
©
For pooled values, the average fold change and frequency of recognition and lowest AUC 
were used.  
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